NEW YORK CITY, NY / ACCESS Newswire / October 22, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Fly-E Group, Inc. ("Fly-E" or "the Company") (NASDAQ:FLYE) and certain of its officers. Class Definition This lawsuit seeks to recover damages against […]

T1 Energy Announces Preliminary Results for Third Quarter 2025 GlobeNewswire October 22, 2025 AUSTIN, Texas and NEW YORK, Oct. 22, 2025 (GLOBE NEWSWIRE) — T1 Energy Inc. (NYSE: TE) (“T1,” “T1 Energy,” or the “Company”) has announced preliminary financial and operating results for the third quarter 2025. Preliminary Third Quarter 2025 Results Overview Total Net

Curanex Pharmaceuticals Inc. Engages Strategic Investor Relations to Enhance Investor Communications and Engagement GlobeNewswire October 22, 2025 Jericho, New York, Oct. 22, 2025 (GLOBE NEWSWIRE) — Curanex Pharmaceuticals Inc. (Nasdaq: CURX) (“Curanex” or the “Company”), a developmental-stage pharmaceutical company focused on discovering and developing botanical drugs for inflammatory diseases, has engaged Strategic Investor Relations, LLC,

Village Farms Introduces Industry-First, One-Way Aroma Valve in Cannabis Packaging Pure Sunfarms brand becomes the first licensed producer in Canada to let consumers see and smell flower before purchase GlobeNewswire October 22, 2025 DELTA, British Columbia, Oct. 22, 2025 (GLOBE NEWSWIRE) — Village Farms International, Inc. (Nasdaq: VFF) today announced another Canadian first innovation from

Mobix Labs Wins Multi-Year U.S. Navy Follow-On Contract as Company Accelerates Growth in Defense and High-Tech Markets GlobeNewswire October 22, 2025 ~ New contract strengthens Mobix Labs' position as a trusted U.S. defense partner ~ ~ Expanding momentum driven by product sales and strategic acquisitions ~ IRVINE, Calif., Oct. 22, 2025 (GLOBE NEWSWIRE) — Mobix

Winnebago Industries Reports Fourth Quarter and Full Year Fiscal 2025 Results GlobeNewswire October 22, 2025 — Favorable Product Mix and Targeted Price Increases Drive Solid Top-Line Growth in Q4 — — Efficiency Actions Contributed to Q4 Operating Cash Flow of $181.4 Million — — Balance Sheet Strength Fortified as Leverage Ratio Improves — — Barletta

Electra Therapeutics Receives FDA Breakthrough Therapy and EMA Priority Medicines Designations for ELA026 in Secondary Hemophagocytic Lymphohistiocytosis (sHLH) GlobeNewswire October 22, 2025 ELA026 has demonstrated promising potential as a frontline treatment for patients with sHLH, a hyperinflammatory disease with high mortality and significant unmet medical need Electra has initiated the SURPASS global pivotal trial evaluating

Electra Therapeutics Announces $183 Million Series C Financing to Advance First-in-Class SIRP-Targeted Therapies for Immune Disorders and Cancer GlobeNewswire October 22, 2025 Proceeds will fund a global pivotal trial of lead product candidate, ELA026, as a frontline treatment for secondary hemophagocytic lymphohistiocytosis (sHLH) Financing will also support indication expansion of ELA026 in hematologic cancers and

Electra Therapeutics Announces First Patients Dosed in the SURPASS Phase 2/3 Pivotal Study of ELA026 in Secondary Hemophagocytic Lymphohistiocytosis (sHLH) GlobeNewswire October 22, 2025 The SURPASS study is enrolling patients at research sites across the U.S. and Europe ELA026 targets signal regulatory proteins (SIRP) as a novel approach to treating the life-threatening hyperinflammatory pathology of

Stifel Reports Third Quarter 2025 Results GlobeNewswire October 22, 2025 ST. LOUIS, Mo., Oct. 22, 2025 (GLOBE NEWSWIRE) — Stifel Financial Corp. (NYSE: SF) today reported net revenues of $1.4 billion for the three months ended September 30, 2025, compared with $1.2 billion a year ago. Net income available to common shareholders was $202.1 million,